BAY 43-9006: Phase II data

In a placebo-controlled Phase II trial in 202 evaluable patients with advanced kidney cancer, BAY 43-9006 met the primary endpoint of

Read the full 214 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE